A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination with Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

Exclusion Criteria

• - History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
• - Symptoms of a clinically significant illness in the 3 months before the study
• - History of hypersensitivity (eg, anaphylaxis), serious allergy, or any serious reaction to carbapenem, cephalosporins, or other β-lactam antibiotics
• - Use within 14 days prior to the first study dose of any over-the-counter (including St. John's Wort or any herbal products) or prescription medication
• - Smoker of more than 5 cigarettes/day or equivalent use of nicotine products during the previous 3 months